PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-8722
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy ; volume:10 ; number:1 ; day:3 ; month:8 ; year:2017 ; pages:1-21 ; date:12.2017
Journal of hematology & oncology ; 10, Heft 1 (3.8.2017), 1-21, 12.2017
- Schlagwort
-
Krebs
Onkologie
- Urheber
-
Long, Junyu
- Beteiligte Personen und Organisationen
-
Lin, Jianzhen
Wang, Anqiang
Wu, Liangcai
Zheng, Yongchang
Yang, Xiaobo
Wan, XueShuai
Xu, Haifeng
Chen, Shuguang
Zhao, Haitao
SpringerLink (Online service)
- DOI
-
10.1186/s13045-017-0511-2
- URN
-
urn:nbn:de:1111-2017101913238
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:22 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Long, Junyu
- Lin, Jianzhen
- Wang, Anqiang
- Wu, Liangcai
- Zheng, Yongchang
- Yang, Xiaobo
- Wan, XueShuai
- Xu, Haifeng
- Chen, Shuguang
- Zhao, Haitao
- SpringerLink (Online service)
Ähnliche Objekte (12)
WNT/β-catenin regulatory roles on PD-(L)1 and immunotherapy responses
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers
Regulation of PD-L1 by PPARg for immunotherapy in gastrointestinal cancers
Regulatory mechanisms of PD-1/PD-L1 in cancers
Combined immunotherapy with anti-PDL-1/PD-1 and anti-CD4 antibodies cures syngeneic disseminated neuroblastoma
Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers : the “all-around warrior” in immunotherapy
Correction: Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers: the “all-around warrior” in immunotherapy
Role of the PD-1/PD-L inhibitory pathway during experimental infection by Trypanosoma cruzi Tulahuen strain
Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective study
First-line hepatic arterial infusion chemotherapy plus lenvatinib and PD-(L)1 inhibitors versus systemic chemotherapy alone or with PD-(L)1 inhibitors in unresectable intrahepatic cholangiocarcinoma
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
WNT/β-catenin regulatory roles on PD-(L)1 and immunotherapy responses
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers
Regulation of PD-L1 by PPARg for immunotherapy in gastrointestinal cancers
Regulatory mechanisms of PD-1/PD-L1 in cancers
Combined immunotherapy with anti-PDL-1/PD-1 and anti-CD4 antibodies cures syngeneic disseminated neuroblastoma
Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers : the “all-around warrior” in immunotherapy
Correction: Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers: the “all-around warrior” in immunotherapy
Role of the PD-1/PD-L inhibitory pathway during experimental infection by Trypanosoma cruzi Tulahuen strain
Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective study
First-line hepatic arterial infusion chemotherapy plus lenvatinib and PD-(L)1 inhibitors versus systemic chemotherapy alone or with PD-(L)1 inhibitors in unresectable intrahepatic cholangiocarcinoma
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
WNT/β-catenin regulatory roles on PD-(L)1 and immunotherapy responses
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers
Regulation of PD-L1 by PPARg for immunotherapy in gastrointestinal cancers
Regulatory mechanisms of PD-1/PD-L1 in cancers
Combined immunotherapy with anti-PDL-1/PD-1 and anti-CD4 antibodies cures syngeneic disseminated neuroblastoma
Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers : the “all-around warrior” in immunotherapy
Correction: Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers: the “all-around warrior” in immunotherapy
Role of the PD-1/PD-L inhibitory pathway during experimental infection by Trypanosoma cruzi Tulahuen strain
Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective study
First-line hepatic arterial infusion chemotherapy plus lenvatinib and PD-(L)1 inhibitors versus systemic chemotherapy alone or with PD-(L)1 inhibitors in unresectable intrahepatic cholangiocarcinoma